Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | ESRRG | P62508 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2728968 | 0.96 | CA2 (0.55) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL580221 | 0.93 | CA2 (0.53) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL24413718 | 0.92 | CA2 (0.52) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL4039313 | 0.91 | CA1 (0.56) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL5264226 | 0.91 | CA2 (0.58) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL938186 | 0.90 | CA1 (0.55) | CA2CA1ESRRGNAMPTTDP1 | |
| SCHEMBL16264885 | 0.88 | TDP1 (0.55) | CA2CA1ESRRGTDP1CA12 | |
| SCHEMBL23449213 | 0.88 | CA2 (0.58) | CA2CA1NAMPTIDO1TDP1 | |
| SCHEMBL20208983 | 0.87 | CA2 (0.55) | CA2CA1ESRRGNAMPTIDO1 | |
| SCHEMBL30958195 | 0.86 | IDO1 (0.48) | CA2CA1ESRRGNAMPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114262321-A | Bistable light-regulated small-molecule protein degradation agent, preparation method and application | 中国药科大学 | 2022-04-01 | — | — | CN | claimed |
| WO-2015162536-A1 | NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE | CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) | 2015-10-29 | — | — | WO | claimed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12540143-B2 | Methods and compositions for targeted protein degradation | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| US-12516018-B2 | Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release | BRANDEIS UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250262308-A1 | Compositions and Methods for Modulating Dopamine Receptor Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-21 | — | — | US | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4522172-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | The Regents of the University of California (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-1997012870-A1 | TETRAHYDROQUINOLINES AS NMDA ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1997-04-10 | — | — | WO | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| US-5451677-A | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1995017888-A1 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0611003-A1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO. INC. (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0369344-B1 | N-arylation of isatins | ABBOTT LAB (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5151518-A | N-arylation of isatins | ABBOTT LABORATORIES (US) | 1992-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | CA2 4004/4885CA1 3828/4885ESRRG 1745/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CA2 2880/4885CA1 3888/4885ESRRG 338/4885 |
| US-12540143-B2 | Methods and compositions for targeted protein degradation | ADRM1, NCOR1, KDELR1 | CA2 4115/4885CA1 3519/4885ESRRG 117/4885 |
| US-20250262308-A1 | Compositions and Methods for Modulating Dopamine Receptor Activity | PARK7, PRLHR, SNCA | CA2 3865/4885CA1 2987/4885ESRRG 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.